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Abstract: 
 
Introduction: Antimicrobial stewardship has an important role in the control of 
Clostridium difficile infection (CDI) and antibiotic resistance. An important 
component of UK stewardship interventions is the restriction of broad-spectrum 
beta-lactam antibiotics and promotion of agents associated with a lower risk of 
CDI such as gentamicin. Whilst the introduction of restrictive antibiotic guidance 
has been associated with improvements in CDI and antimicrobial resistance 
evidence of the effect on outcome following severe infection is lacking. 
 
Methods: In 2008, Glasgow hospitals introduced a restrictive antibiotic guideline. 
A retrospective before/after study assessed outcome following gram-negative 
bacteraemia in the 2-year period around implementation. 
 
Results: Introduction of restrictive antibiotic guidelines was associated with a 
reduction in utilisation of ceftriaxone and co-amoxiclav and an increase in 
amoxicillin and gentamicin. 1593 episodes of bacteraemia were included in the 
study. The mortality over 1 year following gram-negative bacteraemia was lower 
in the period following guideline implementation (RR  0.852, P = 0.045). There 
was no evidence of a difference in secondary outcomes including ITU admission, 
length of stay, readmission, recurrence of bacteraemia and need for renal 
replacement therapy. There was a fall in CDI (RR 0.571, P = 0.014) and a 
reduction in bacterial resistance to ceftriaxone and co-amoxiclav but no evidence 
of an increase in gentamicin resistance after guideline implementation. 
 
Conclusion: Restrictive antibiotic guidelines were associated with a reduction in 
CDI and bacterial resistance but no evidence of adverse outcomes following 
gram-negative bacteraemia. There was a small reduction in one year mortality. 
 
 
 1. Introduction 
 
Delay in delivery of appropriate antibiotic therapy in severe bacterial infection is 
associated with poor outcome(1).The rising prevalence of antibiotic 
resistance(2) and the increasing incidence of Clostridium difficile infection 
(CDI)(3) have  been associated with antibiotic prescribing,(4-6) and particularly 
with broad-spectrum agents such as cephalosporins and quinolones (6,7). 
Antimicrobial stewardship programmes aim to limit prescribing of broad-
spectrum antibiotics to specific preserved indications where possible. A 
systematic review demonstrated that published stewardship strategies have 
been associated with significant reductions in CDI(8) and a positive impact on 
gram negative resistance have also been observed(9,10). Such strategies are now 
recommended by guidelines in the United Kingdom(11) and elsewhere(12). As in 
other parts of the UK (13), the Scottish stewardship strategy has focused on 
reducing use of ‘4C’ antibiotics: cephalosporins, co-amoxiclav, ciprofloxacin (and 
other quinolones) and clindamycin(14). 
 
NHS Greater Glasgow and Clyde (population 1.2 million) introduced a 
comprehensive “4C” restrictive antimicrobial guideline across the 9 acute adult 
hospitals from July to August 2008. Similar restrictive guidance were developed 
and rolled out across primary care in 2009.  Changes were made primarily in 
response to concerns regarding CDI with reported rates of 2.04 per 1000 
occupied bed days for those aged ≥65 years in 2006/2007 
{http://www.documents.hps.scot.nhs.uk/hai/sshaip/publications/cdad/2007-
12-20-ar-cdad.pdf.}  Updated guidelines recommended gentamicin in 
combination with narrow-spectrum beta-lactams instead of broad-spectrum 
beta-lactams (principally ceftriaxone or co-amoxiclav) for suspected severe 
gram-negative infection (table 1). Gram-negative resistance to gentamicin in 
Glasgow at this time was lower than the agents it replaced and its use was 
perceived to be associated with a lower risk of CDI than ‘4C’ antibiotics(15).  
At the time of guideline implementation, concerns around promoting a greatly 
expanded role for gentamicin were considered. Specific concerns included the 
potential for increased incidence of acute kidney injury and ototoxicity as well as 
the relative paucity of data supporting the use of gentamicin monotherapy in 
severe infection(16,17). In view of the potential for unintended harm, it was 
recommended that gentamicin was restricted to the empiric phase of therapy 
with a maximum duration of 4 days. Within the restrictive guidance the 
importance of early recognition and investigation of sepsis with prompt 
intravenous antibiotic therapy was emphasized. Updated guidance was made 
available through educational meetings, electronic communication and intranet, 
posters and via the Health Board’s Therapeutics handbook. In order to assess the 
impact of the restrictive antimicrobial policy on outcome (including unintended 
consequences) of severe gram-negative infection following the introduction of 
the updated guidelines we designed a pragmatic before/after cohort study. 
 
2. Methods 
 
Data were collected retrospectively from patients presenting to the 4 acute adult 
hospitals in North Glasgow (around 2600 beds). Blood cultures yielding gram-
negative organisms over the two-year period spanning guideline introduction 
(1/8/2007–31/7/2009) were screened for inclusion. Outcome data were 
collected from prospectively maintained databases held within our NHS board. 
Hospital associated infection (HAI) was defined as bacteraemia which occurred 
in a patient admitted to hospital more than two days prior to the blood culture or 
who had been discharged within 28 days(adapted from 18). Throughout the 
period of study, antimicrobial sensitivity testing was conducted using disk 
diffusion testing according to CLSI guidelines. Antimicrobial utilisation data is 
presented in defined daily doses per 103 occupied bed days [DDD])(19). 
 
Outcome definitions 
 
Recurrence was defined as gram-negative bacteraemia detected more than 48 
hours after the initial blood culture.  The detection of Clostridium difficile toxin in 
diarrhoeal stool was considered diagnostic of CDI. Need for renal replacement 
therapy (RRT) was defined as commencement of haemofiltration or 
haemodialysis in a patient who had not received RRT within the prior 60 days 
and had not been diagnosed with end stage renal disease. Serum creatinine was 
retrieved at admission and on days 7, 30 and 60 as long as the patient remained 
in hospital. Renal function was assessed using the modification of diet in renal 
disease (MDRD) estimate of glomerular filtration rate (eGFR). Kidney injury was 
classified according to the RIFLE criteria(20).  
 
Statistical Analysis 
 
Survival and outcome analysis was conducted using Cox proportional hazard 
modeling. Modeling of the impact of CDI on survival during multivariate analysis 
was conducted via a step parameter to avoid immortal-time bias. Analysis of 
bacterial resistance was conducted using 2x2 contingency tables and Fisher’s 
exact test. 
 
Statistical analysis was conducted using R for OS X 3.0.2. Plots were generated 
using ggplot2 0.9.3 and Prism 6.0 (Graphpad). 
 
Ethics and Funding Statement 
 
The regional ethics committee scientific advisor gave advice that the study 
represented service evaluation and did not require formal ethical review. 
Permission to use patient identifiable information was obtained from the 
Cauldicott Guardian. The research study was designed by the authors and no 
funding was received to assist in conducting it. 
 
3. Results 
 
1593 episodes of bacteraemia were included from 2350 positive blood cultures 
screened (figure 1). 791 (49.7%) episodes of bacteraemia were from the period 
prior to the introduction of the new guidelines (period 1) whereas 802 (50.3%) 
occurred after the change (period 2). There was no change in the incidence of 
bacteraemia over the study period. There was no evidence of a difference in the 
baseline characteristics of the patients and organisms isolated (table 2). 
 There was a significant change in antibiotic requisitions throughout North 
Glasgow hospitals in association with the new guidelines (figure 2A) with 
increased use of amoxicillin (173 and 269 DDD) and gentamicin (27.4 and 45.1 
DDD) but decreased use of ceftriaxone (46.3 and 13.2 DDD), co-amoxiclav (18.1 
and 12.7 DDD) and ciprofloxacin (11.0 and 9.1 DDD) (all P < 0.001). There was 
no evidence of an increase in the use of meropenem (18.1 and 20.5 DDD, P = 
0.15) or piperacillin/tazobactam (16.3 and 16.9 DDD, P = 0.50) although the 
power to detect small increases in use of antibiotics was limited by the number 
of data points available. There was a significant increase in gentamicin 
therapeutic drug monitoring (TDM) within a week of the positive blood culture 
in period 2 (30% to 59%, P<0.0001, figure 2B). 
 
Mortality in the gram-negative bacteraemia cohort at one year was lower in 
period 2 than in period 1 (RR 0.852, 95% CI 0.73 – 0.99, P = 0.045) (figure 3A). 
Lower mortality was observed in HAI (RR 0.808, 95% CI 0.67 – 0.98, P = 0.027) 
but not CAI (RR 0.950, 95% CI 0.72 – 1.26, P = 0.72) (figure 3B). 
 
There was no difference in outcome between time periods in terms of ITU 
admission (RR 1.095, 95% CI 0.72 – 1.67, P = 0.667), length of stay (median 11 
days in both groups, P = 0.769) or recurrence of gram-negative bacteraemia with 
either the same (HR = 1.19 [0.78 – 1.81], P = 0.431) or a different species (HR = 
1.04 [0.74 – 1.45], P = 0.835). Patients in period 2 were significantly less likely to 
develop CDI (HR = 0.57 [0.37 – 0.89], P = 0.014) (figure 4). 
 
There was a significant change in gram-negative bacterial resistance following 
the introduction of the updated guidelines. There was a significant reduction in 
resistance to ceftriaxone (-4.7%, P = 0.020) and co-amoxiclav (-5.8%, P = 0.022) 
and a trend towards less resistance to piperacillin/tazobactam (-2.3%, P = 
0.109). There was no evidence of an increase in resistance to gentamicin (0.5%, 
P = 0.735). In each case, the reduction in antimicrobial resistance observed was 
principally seen in patients with HAI with smaller, non-significant changes in 
bacterial resistance in CAI (figure 5). The proportion of bacteria sensitive to the 
guideline antibiotic regimen for gram-negative sepsis at the time of the 
bacteraemia increased from 79.1% to 90.0% (+10.9% [7.4 – 14.5], P < 0.0001) 
although this increase was primarily due to the lower prevalence of gentamicin 
resistance relative to that of ceftriaxone rather than the change in the sensitivity 
pattern of the organisms. 
 
Serum creatinine measurements were available for the duration of each patient’s 
admission to hospital. No difference in baseline renal function was observed 
(Baseline Cr: 140 and 137 mmol/l, P = 0.63) and there was no evidence of a 
difference in renal function at any of the follow up time points (P = 0.86). We 
were concerned that patients presenting with abnormal renal function (Injury, 
Failure or Loss in the RIFLE classification) at baseline might be at risk from the 
new guidelines. After excluding patients with normal renal function at baseline, 
there was a statistically non-significant trend towards a slower renal recovery in 
period 2 (P = 0.14, figure 6) and more patients with abnormal renal function at 
baseline in period 2 had a worsening of renal function over the first week of 
admission (RR 1.50, P = 0.02). There was no evidence of a difference in median 
length of stay or mortality in this group. We also analysed the same data 
categorically using the RIFLE classification in place of eGFR with similar results. 
 
4. Discussion 
 
The impact of restrictive antimicrobial guidelines on reducing the rate of CDI(8) 
and bacterial resistance(9,10) has been reported before and this study provides 
further evidence of benefit from stewardship. However, a Cochrane review of 
outcomes following restrictive antimicrobial stewardship interventions did not 
find any reports on clinical outcomes except CDI and resistance(21).  This is 
particularly important in view of historic findings from randomized controlled 
trials of gentamicin efficacy. A meta-analysis of clinical trials involving 
gentamicin found similar outcomes to comparator antibiotics but only a small 
proportion of patients had sepsis(16). Another meta-analysis of heterogenous 
studies in secondary peritonitis found lower rates of clinical cure in patients 
treated with clindamycin and gentamicin although mortality was not 
affected(17). Clinical outcome data following severe infection managed using 
restrictive guidelines are extremely limited. One study (published only in 
abstract) which examined the mortality from “septicaemia” using discharge 
coding, found a 21% reduction in mortality after the introduction of restrictive 
guidelines similar to those used in Glasgow(22). In another uncontrolled study, 
treatment failure following the introduction of restrictive guidelines was 
associated with failure to administer guidelines antibiotics(23). To our 
knowledge, the pragmatic before/after study we report here is the first 
controlled study to investigate survival following severe infection in association 
with such guidelines. This is important since the primary goal of antimicrobial 
guidelines must be to assist clinicians in giving effective therapy for severe 
infection. The desire to limit antibiotic associated harm must not be at the 
expense of less effective therapy for sepsis. Although a lack of association 
between the increase in gentamicin prescribing across Glasgow hospitals and the 
need for RRT was previously demonstrated(24), a gentamicin based regime for 
orthopaedic surgical prophylaxis in some Scottish hospitals was associated with 
an increase in renal dysfunction(21,25). This reinforces the importance of 
vigilance for identification of unintended consequences when implementing 
antibiotic guidelines. An evidence base for stewardship programs is also 
important for acceptance; opposition from prescribing clinicians is frequently 
cited as an important barrier to success of stewardship interventions(26). In our 
experience, concern about the efficacy of narrow-spectrum alternatives is a 
commonly cited reason for opposition – this study was conducted partly in 
response to these concerns. 
 
In this study we have shown that a restrictive antimicrobial stewardship policy 
applied across acute hospitals in North Glasgow was not associated with 
detectable worsening in the outcome following serious gram-negative infection. 
An overall reduction in mortality was observed and was, attributable to those 
with hospital-associated gram-negative bacteraemia. There was a significant 
reduction in CDI following the introduction of the restrictive guidelines and, 
since gentamicin resistance was less common in Glasgow than resistance to 
previously used first line agents, patients treated according to the guidelines 
were more likely to receive effective antibiotic therapy. Since CDI and infection o m
 
with resistant organisms are associated with poor outcome and are more 
common in patients with HAI, it may be that these factors contributed to the 
difference observed and this hypothesis was supported by multivariate analysis 
(data not shown). However, despite accounting for these factors, there was still 
no clear evidence of increased risk of adverse outcome in patients treated under 
the restrictive guidelines. The absence of an increased need for renal 
replacement therapy was also reassuring since gentamicin associated 
nephrotoxicity is a particular concern. A modified version of the Hartford 
nomogram (27) with an online dosing calculator based on a gentamicin dose of 5 
mg/kg 24 or 48 hourly was developed and is used in Glasgow hospitals(28). 
 
Renal failure is strongly associated with prolonged length of stay and mortality 
in many studies(29,30). Once daily dosing of aminoglycosides may be associated 
with decreased nephrotoxicity and improved clinical response compared with 
multiple daily dosing in some patient groups(31). Gentamicin nephrotoxicity has 
been associated with treatment duration(32,33); Glasgow guidelines recommend 
limiting gentamicin therapy duration to three or four days to reduce the risk of 
nephrotoxicity. Renal replacement therapy is an easily recorded outcome of 
renal failure, however it represents only the tip of the iceberg. There was no 
evidence of an impact of guideline change on renal function overall in our study. 
When the subgroup of patients with abnormal renal function at baseline was 
considered there was a trend towards delayed recovery of renal function. 
However, the trend effect was small and there was no evidence of impact on 
length of stay, nor need for renal replacement therapy or mortality. 
 
An important limitation of this study is that individual prescribing data were not 
available. However, use of gentamicin TDM within the gram-negative 
bacteraemia cohort could be used as a surrogate for gentamicin therapy. It 
should be noted that despite the introduction of the updated guidelines, more 
than 40% of patients did not have gentamicin TDM. There are a number of 
potential reasons for this: a small number of patients may have received 
gentamicin but were switched to an alternative antibiotic or died prior to a TDM 
but the majority are likely to have received non-guideline antibiotics. This 
reflects the pragmatic nature of the guidelines, which encouraged discussion 
with infection specialists and did not impose procedural restraint on clinicians 
recommending non-guideline antibiotics. Patients with gram-negative sepsis are 
often among the most unwell patients and it is therefore not surprising that 
these patients are likely to receive individualised therapy. This study cannot 
purport to present evidence that gentamicin should be given to all unselected 
patients with suspected gram-negative sepsis. It does, however, provide 
significant reassurance that restrictive guidelines promoting the use of 
gentamicin, pragmatically applied, can be safely used as part of an antibiotic 
stewardship programme.  
 
A general limitation of before/after studies is the difficulty in establishing 
causation of differences observed. The restrictive antimicrobial policy was 
introduced at a similar time to other linked interventions including an increased 
focus on infection control, health-care associated infection and prompt 
management of sepsis. The educational role out of the restrictive guidance in fact 
incorporated all these factors and particularly emphasized the importance of 
prompt administration of parenteral antibiotic therapy in acutely unwell 
patients with infection. These and other unidentified factors may have 
significantly influenced outcome. Most successful strategies for reduction of CDI 
and antibiotic resistance incorporate interventions in both infection control and 
antibiotic stewardship; for this reason data assessing the impact of each in 
isolation are limited. Other experimental designs would be extremely difficult 
and costly to implement, so pragmatic before/after studies are likely to form the 
bulk of available data to guide practice. 
 
In conclusion, the change to the empirical antibiotic guidelines in Glasgow 
hospitals was associated with a decrease in CDI, antibiotic resistance in gram-
negative bacteraemia and a modest but significant reduction in mortality 
following Gram-negative bacteraemia but not with a significant increase in renal 
failure. This study provides evidence that restrictive antibiotic policies 
promoting the widespread use of empirical (short duration) gentamicin are 
effective. 
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 Figure 1. 
 
Flowchart illustrating the identification of episodes of bacteraemia suitable for 
inclusion from the microbiology database. 
 
Figure 2. 
 
Antibiotic utilization data for period covering the introduction of restrictive 
antibiotic guidelines. Temporal trends in (A)pharmacy dispensing records and 
(B) gentamicin therapeutic drug monitoring within one week of detection of 
gram-negative bacteraemia. DDD: designated daily dose. 
 
Figure 3. 
 
Survival for 1 year following episode of bacteraemia before and after the 
introduction of restrictive antimicrobial guidelines.A. All patients. B. Stratified 
according to status of infection. CAI: community associated infection; HAI: 
hospital associated infection. P values shown are for log rank test. 
 
Figure 4. 
 
Analysis of pre-specified secondary end-points. Outcomes were assessed by 
univariate Cox proportional hazard model and represent relative risk of outcome 
except for length of stay which represents relative change in median time to 
discharge. IQR: inter-quartile range; ITU: intensive care unit; CAI: community 
associated infection; HAI: hospital associated infection. 
 
Figure 5. 
 
Change in rate of bacterial resistance to commonly used antibiotics between 
period 1 and period 2 and stratified according to hospital or community 
associated infection. Bars represent change in resistance with error bars 
showing 95% confidence intervals. CAI: community associated infection; HAI: 
hospital associated infection. 
 
Figure 6. 
 
Change in serum creatinine after detection of gram-negative bacteraemia in 
patients treated in period 1 and period 2 stratified according to RIFLE 
classification at baseline. Line represents mean serum creatinine at each time 
point with 95% confidence interval denoted by error bar. 
 Source of sepsis Period to July 2008 Period after July 2008 
Undifferentiated  Ceftriaxone ± gentamicin Benzylpenicillin + flucloxacillin + 
gentamicin 
Urinary tract Ceftriaxone or co-amoxiclav ± 
gentamicin 
Amoxicillin + gentamicin 
Intra-abdominal  Ceftriaxone + metronidazole ± 
gentamicin 
Amoxicillin + gentamicin + 
metronidazole 
Table i. Guideline antibiotic therapy for patients presenting with sepsis syndrome likely to be 
caused by gram-negative organisms before and after the introduction of revised guidelines. 
 Characteristic 2007/2008 2008/2009 P value 
Median age (IQR) 69.9 (56.6-79.2) 69.3 (54.6-79.7) 0.50 
Male sex (%) 387 (48.6%) 384 (47.3%) 0.61 
Source dept. Medicine 324 (40.7%) 369 (45.5%) 
0.21 
 Surgery 201 (25.3%) 201 (24.8%) 
 Emergency 151 (19.0%) 132 (16.2%) 
 Other 119 (15.0%) 109 (13.4%) 
Hospital assoc. 449 (56.4) 452 (55.7) 0.80 
Causative organism E. coli 415 (52.2%) 457 (56.4%) 
0.38 
 Other coliforms 242 (30.4%) 225 (27.7%) 
 Pseudomonas sp. 33 (4.2%) 28 (3.4%) 
 Others 105 (13.2%) 100 (12.3%) 
Table ii. Baseline characteristics of patients with gram-negative bacteraemia and microbiological 
identification of isolates. 
 
 
Abbreviations 
CDI Clostridium difficile infection 
DDD Defined daily dose/103 occupied bed days 
RRT Renal replacement therapy 
MDRD modification of diet in renal disease eGFR 
TDM Therapeutic drug monitoring 
HAI Hospital acquired infection 
CAI Community acquired infection 
eGFR Estimated glomerular filtration rate 
 
  
 
 
Figure 1. Flowchart illustrating the identification of episodes of bacteraemia suitable for inclusion from the 
microbiology database.  
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Figure 2. Antibiotic utilization data for period covering the introduction of restrictive antibiotic guidelines. 
Temporal trends in (A)pharmacy dispensing records and (B) gentamicin therapeutic drug monitoring within 
one week of detection of gram-negative bacteraemia. DDD: designated daily dose.  
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Figure 3. Survival for 1 year following episode of bacteraemia before and after the introduction of restrictive 
antimicrobial guidelines.A. All patients. B. Stratified according to status of infection. CAI: community 
associated infection; HAI: hospital associated infection. P values shown are for log rank test.  
figure 3  
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Figure 4. Analysis of pre-specified secondary end-points. Outcomes were assessed by univariate Cox 
proportional hazard model and represent relative risk of outcome except for length of stay which represents 
relative change in median time to discharge. IQR: inter-quartile range; ITU: intensive care unit; CAI: 
community associated infection; HAI: hospital associated infection.  
figure 4  
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Figure 5. Change in rate of bacterial resistance to commonly used antibiotics between period 1 and period 2 
and stratified according to hospital or community associated infection. Bars represent change in resistance 
with error bars showing 95% confidence intervals. CAI: community associated infection; HAI: hospital 
associated infection.  
figure 5  
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Figure 6. Change in serum creatinine after detection of gram-negative bacteraemia in patients treated in 
period 1 and period 2 stratified according to RIFLE classification at baseline. Line represents mean serum 
creatinine at each time point with 95% confidence interval denoted by error bar.    
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